Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/33879
Type
ArticleCopyright
Open access
Embargo date
2020-07-08
Collections
Metadata
Show full item record
PREVENTIVE THERAPY FOR HIV-ASSOCIATED TUBERCULOSIS
Author
Affilliation
Fundação Oswaldo Cruz. Presidência. Centro de Estudos Estratégicos. Rio de Janeiro, RJ, Brasil / Federal University of Rio de Janeiro. Instituto de Doenças do Tórax. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia. Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia. Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Abstract
Purpose of review: Tuberculosis (TB) remains the leading cause of death in people living with HIV (PLHIV) despite the achievements in antiretroviral therapy coverage. TB preventive therapy (TPT) has proved efficacy but has been neglected and poorly implemented. We reviewed recent publications and guidelines about TPT in
PLHIV. Recent findings: High-quality studies showed that TPT has a durable effect, over 5 years, preventing TB and all-cause mortality. There is new evidence showing the noninferiority of shorter, rifamycin-based regimens of TPT increasing the options for treatment. Recent studies describing robust implementation in different settings showed promising results for feasibility, tolerance, retention, and cost-effectiveness. New WHO
recommendations, unifying previous versions, have been released to guide countries implementation. Summary: New evidence support the scale up of TPT for PLHIV globally, further studies are needed to bring more evidence for specific populations, like pregnant women and for drug–drug interactions with antiretroviral
agents.
Share